XJPX
6869
Market cap7.18bUSD
Oct 09, Last price
1,855.00JPY
1D
-1.43%
1Q
21.16%
Jan 2017
-17.80%
Name
Sysmex Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Kobe, Japan, Sysmex Corporation is a global leader in the creation, production, and distribution of sophisticated diagnostic instruments, chemical reagents, and related software. Their extensive product portfolio addresses a wide array of laboratory needs. Within hematology, Sysmex provides advanced three-part and five-part white blood cell differentiation instruments, alongside efficient transport systems designed for high-throughput laboratory environments. Their offerings further encompass automated analyzers for both urine particles and blood coagulation. The company also specializes in automated immunochemistry systems, capable of performing intricate assays on minute sample volumes, complemented by reagents for detecting infectious diseases and tumor markers. Additionally, Sysmex manufactures essential flow cytometers utilized in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core diagnostic tools, Sysmex offers specialized systems for detecting cancer lymph node metastasis and provides comprehensive laboratory assay services. The company's operations extend into developing and commercializing software for diagnostic information systems, and delivering a range of services including facility management, administrative support, employee welfare, and genetic analysis. They are deeply involved in the conception, operation, and maintenance of IT solutions, platforms, and applications tailored for digital medicine. Sysmex also actively participates in the entire lifecycle of medical robots, from marketing and development to design, manufacturing, sales, and post-sales support. Furthermore, the company manages the distribution and after-sales support for medical devices and reagents used across biotechnology, medical technology, and molecular cell analysis. Sysmex is committed to research, development, manufacturing, and commercialization of regenerative medicine products and biodevices, while also developing, maintaining, and selling general computer software and offering blood DNA testing services. Sysmex serves a diverse international client base, including national and public hospitals, private healthcare facilities, universities, research institutions, and various other medical organizations. Their global reach is substantial, with product exports to approximately 190 countries. Founded in 1968, the company initially operated as TOA Medical Electronics Co., Ltd., adopting the name Sysmex Corporation in October 1998.
Related entities
Subsidiaries
SYSMEX AMERICA, INC.
Key people
Hisashi Ietsugu
Chairman of the Board, Group Chief Executive Officer, Representative Director · since 2023
Tomokazu Yoshida
Managing Executive Officer, Chief Technology Officer, Director · since 2023
Takashi Ono
Managing Executive Officer, Director · since 2023
Frank Buescher
Senior Executive Officer · since 2023
Kensuke Iizuka
Senior Executive Officer · since 2023
Mitsuhisa Kanagawa
Senior Executive Officer · since 2024
Alain Baverel
Executive Officer · since 2020
Andy Hay
Executive Officer · since 2022
Naohiko Matsuo
Executive Officer, Chief Director of ICH (Immunology/Biochemistry/Blood Coagulation) Business · since 2023
Takaaki Nagai
Executive Officer, Manager of Product Design Center · since 2024
Zuohui Peng
Executive Officer · since 2017
Kenji Tsujimoto
Executive Officer, Manager of Next Generation Medical Business Development Office · since 2024
Kinya Uchihashi
Executive Officer, Chief Director of Diagnostic Reagent Production · since 2021
Kaoru Watanabe
Executive Officer · since 2021
Reiko Watanabe
Executive Officer, Chief Director of Clinical Strategy and Academic Division · since 2023
Tomoo Aramaki
Director · since 2022
Kenji Tachibana
Senior Managing Executive Officer, Director · since 2021
Independent Director · since 2024
Independent Director · since 2020
Haruo Inoue
Independent Director · since 2024
Headquarters & legal address
中央区脇浜海岸通1丁目5番1号
神戸市, 28 651-0073
JP
神戸市, 28 651-0073
JP
Other language
Sysmex Corp.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||